Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Boehringer Ingelheim
Baxter
Express Scripts
Merck

Last Updated: January 24, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Penclomedine


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Penclomedine?

Penclomedine is an investigational drug.

There have been 7 clinical trials for Penclomedine. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.

The most common disease conditions in clinical trials are Neoplasms, Lymphoma, and Neoplasms, Second Primary. The leading clinical trial sponsors are National Cancer Institute (NCI), DEKK-TEC, Inc., and Sidney Kimmel Comprehensive Cancer Center.

There are sixty-four US patents protecting this investigational drug and five hundred and seventy-five international patents.

Recent Clinical Trials for Penclomedine
TitleSponsorPhase
DM-CHOC-PEN Plus Radiation for Brain TumorsNational Cancer Institute (NCI)Phase 1
DM-CHOC-PEN Plus Radiation for Brain TumorsDEKK-TEC, Inc.Phase 1
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain TumorsDetroit Clinical Research Center, Farmington Hills, Lansing and Owasso, MIPhase 2

See all Penclomedine clinical trials

Clinical Trial Summary for Penclomedine

Top disease conditions for Penclomedine
Top clinical trial sponsors for Penclomedine

See all Penclomedine clinical trials

US Patents for Penclomedine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Penclomedine ⤷  Sign up for a Free Trial Methods and systems for predicting cancer outcome H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL) University of South Florida (Tampa, FL) ⤷  Sign up for a Free Trial
Penclomedine ⤷  Sign up for a Free Trial Dosage regimen for a PI-3 kinase inhibitor NOVARTIS AG (Basel, CH) ⤷  Sign up for a Free Trial
Penclomedine ⤷  Sign up for a Free Trial Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor Novartis AG (Basel, CH) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Penclomedine

Drugname Country Document Number Estimated Expiration Related US Patent
Penclomedine European Patent Office EP1894131 2025-02-25 ⤷  Sign up for a Free Trial
Penclomedine World Intellectual Property Organization (WIPO) WO2005083128 2024-02-25 ⤷  Sign up for a Free Trial
Penclomedine World Intellectual Property Organization (WIPO) WO2006093507 2024-02-25 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Boehringer Ingelheim
Baxter
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.